

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 10-QSB

**/x/ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934**

FOR QUARTERLY PERIOD ENDED SEPTEMBER 30, 2003

OR

**// TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934**

FOR THE TRANSITION PERIOD FROM _____ TO _____.

COMMISSION FILE NUMBER 0-49824

INAMCO INTERNATIONAL, CORP.

(Exact name of small business issuer as specified in its charter)

DELAWARE
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR
ORGANIZATION)

72-1359595
(I.R.S. EMPLOYER
IDENTIFICATION NO.)

801 Montrose Ave., South Plainfield, NJ
(ADDRESS OF PRINCIPAL
EXECUTIVE OFFICES)

07080
(ZIP CODE)

(908) 754-4880
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes /x/ No //

Indicate the number of shares outstanding of each of issuer's classes of
common stock, as of the latest practicable date.

**COMMON STOCK, \$0.00001
PAR VALUE**

4,994,633 SHARES

Class

Outstanding as of November 19, 2003

INAMCO INTERNATIONAL, CORP.
(A Development Stage Company)

INDEX

	PAGE NO.
PART I. FINANCIAL INFORMATION	
Item 1. Financial Statements (Unaudited)	3
Condensed Balance Sheets—As of September 30, 2003 and December 31, 2002	3
Condensed Statements of Operations—Three and Nine Month Ended September 30, 2003 and 2002	4
Condensed Statements of Cash Flows—Nine Month Ended September 30, 2003 and 2002	5
Notes to Condensed Financial Statements	6
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	8
Item 3. Controls and Procedures	10
PART II. OTHER INFORMATION	
Item 4. Exhibits and Reports on Form 8-K	11
Signatures	11
Exhibit 31	12
Exhibit 32	13

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Inamco International, Corp.
(A Development Stage Company)

Condensed Balance Sheets

	September 30, 2003	December 31, 2002
	(unaudited)	(Note)
ASSETS		
Current assets:		
Cash	\$ 92	\$ 927
Total Current Assets	92	927
Other Assets	\$ 213	\$ 213
Total Assets	\$ 305	\$ 1,140
LIABILITIES AND STOCKHOLDERS' DEFICIENCY		
Current liabilities:		
Accounts payable and accrued expenses	\$ 10,189	\$ 5,615
Total Current liabilities	10,189	5,615
Due to Officers/Shareholders	20,123	8,069
Total Liabilities	30,312	13,684
Stockholders' Deficiency:		
Common stock, \$0.00001 par value;		
Authorized: 50,000,000 shares		
Issued and Outstanding: 27,600,000 shares	276	276
Additional paid-in capital	22,804	22,804
Deficit Accumulated in the Development Stage	(53,087)	(35,624)
Total Stockholders' Deficiency	(30,007)	(12,544)
Total liabilities and stockholders' equity	\$ 305	\$ 1,140

Note: These balance sheets have been derived from unaudited financial statements and do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

See accompanying notes to condensed financial statements.

Inamco International, Corp.
(A Development Stage Company)

Condensed Statements of Operations
(Unaudited)

	Three months ended September 30,	
	2003	2002
Revenues		
Total revenues	\$ —	\$ —
Cost and Expenses		
Bank Charges and Miscellaneous	44	39
Professional and Consulting Fees	7,987	—
Total operating expenses	8,031	39
Net Loss	\$ (8,031)	\$ (39)
Net (loss) per share	\$ (0.00)	\$ (0.00)
Weighted Average Number of Shares Outstanding	27,600,000	27,600,000

	Nine months ended September 30,	
	2003	2002
Revenues		
Total revenues	\$ —	\$ —
Cost and Expenses		
Bank Charges and Miscellaneous	134	539
Professional and Consulting Fees	17,329	—
Total operating expenses	17,463	539
Net Loss	\$ (17,463)	\$ (539)
Net (loss) per share	\$ (0.00)	\$ (0.00)
Weighted Average Number of Shares Outstanding	27,600,000	27,600,000

See accompanying notes to condensed financial statements.

Inamco International, Corp.
(A Development Stage Company)

Condensed Statements of Operations
(Unaudited)

Inception (January 17,
1993) to September 30,

	2003
Revenues	
Total revenues	\$ —
Cost and Expenses	
Bank Charges and Miscellaneous	307
Professional and Consulting Fees	52,779
Total operating expenses	53,086
Net Loss	\$ (53,806)
Net (loss) per share	\$ (0.00)
Weighted Average Number of Shares Outstanding	14,932,480

Condensed Cash Flow Statements (Unaudited)

Nine months ended September 30,

	2003	2002
Cash Flows from Operating Activities		
Net income (loss)	\$ (17,463)	\$ (539)
Adjustments to reconcile net loss to net cash used in operating activities:		—
Change in accrued expenses	4,574	(1,653)
Net cash used for operating activities	(12,889)	(2,192)
Cash Flows from Investing Activities		
Change in other assets	—	—
Net cash used for investing activities	—	—
Cash Flows from Financing Activities		
Loans from officer/shareholder, net of repayments	12,054	2,168
Restricted common stock issued in payment of expenses	—	—
Net cash provided by financing activities	12,054	2,168
NET INCREASE (DECREASE) IN CASH	(835)	(24)
Cash at beginning of period	927	38
Cash at end of period	\$ 92	\$ 14

See accompanying notes to condensed financial statements.

NOTES TO CONDENSED UNAUDITED FINANCIAL STATEMENTS

1. Basis of Presentation

In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of (a) results of operations for the nine and three month periods ended September 30, 2003 and 2002 (b) the financial position at September 30, 2003, and (c) the statements of cash flows for the nine month period ended September 30, 2003 and 2002 have been made. The results of operations for the nine and three months ended September 30, 2003 are not necessarily indicative of the results to be expected for the full year.

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for financial statements. For further information, refer to the audited financial statements and notes thereto for the year ended December 31, 2002 included in the Company's Form 10-KSB filed with the Securities and Exchange Commission on April 15, 2003.

The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect amounts reported in the condensed financial statements and related footnotes. Changes in the estimates may affect amounts reported in future periods.

The company is in the development stage as defined I Financial Accounting Standards Board Statement NO. 7. It has not commenced full scale operations and has insignificant assets. The financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has no significant assets, no revenues and has had losses since inception. The Company can only become a viable going concern if it obtains additional capital and acquires a viable operating company.

2. Net Loss Per Share

In accordance with SFAS No. 128, Earnings Per Share basic and diluted net loss per share are computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period.

3. Comprehensive Loss

Comprehensive loss for all periods presented is the same as net loss.

4. Deferred Stock Compensation

For the nine months ended September 30, 2003 and 2002, in connection with advisory and consultation to second party firms, the Company recorded no deferred stock compensation.

5. Non-cash Preferred Stock Charge

For the nine months ended September 30, 2003 and 2002, the Company recorded no sale of any forms of Preferred Stock.

6. Capital Purchase of Common Stock by a Privately Held Business

On October 26, 1999, the Company, which was previously known as Omni Assets, Inc. (a "non-operating" public shell), sold 22,273,890 of its common shares of stock to Inamco International Corp. (a privately held corporation). The acquisition was deemed to be a capital purchase, by privately held corporations, of the majority amount of common shares owned by Omni Assets, Inc. In January 2000,

Omni then purchased the name of “Inamco International Corp.”, and in February 2000, the Company changed its name from “Omni Assets, Inc.” to “Inamco International Corp.”. The listing symbol was changed from “OMNA” to “IICO”. The Company subsequently performed a 1-for-1000 reverse split of its common share of stock, effective October 2, 2003, thus causing its listing symbol to change from “IICO” to “IICC”. As of September 30, 2003 however, the total number of shares outstanding equaled Twenty Seven Million Six Hundred Thousand (27,600,000).

The following table provides information pertaining to owners of more than five percent of any class of the Company’s common stock as of September 30, 2003.

(1) Title of Class	(2) Name and Address of Beneficial Owner	(3) Amount and Nature of Beneficial Owner	(4) Percentage of Ownership
Common A	Inamco Services Corp.* 801 Montrose Ave. South Plainfield, NJ 07080	12,947,487	46.91%
Common A	Advanced Diagnostics Inc.* 801 Montrose Ave. South Plainfield, NJ 07080	7,976,393	28.89%

Security ownership of management.

The following table provides information pertaining to shares beneficially owned by all directors and nominees.

(1) Title of Class	(2) Name and Position of Beneficial Owner	(3) Amount and Nature of Beneficial Owner	(4) Percentage of Ownership
Common A	Varges George* President/Secretary	21,923,880	79.43%

Mr. Varges George is the sole shareholder of Inamco Services Corp., and Advanced Diagnostics Inc., as described herein. Accordingly, Mr. George has direct control of approximately 79.43% of Inamco International, Corp.’s outstanding common shares of stock that is inclusive of 1,000,000 shares owned directly in his name.

7. Follow-on Offering of Common Stock

For the nine months ended September 30, 2003, the Company has not recorded and/or performed any secondary or private offering sale of securities.

8. Contingencies

On October 29, 2003, the Company, its subsidiaries and Varges George, the principal shareholder of the Company were sued by H. Neil Broder based on an alleged breach of contract claim. Mr. Broder alleges that he provided legal services to Mr. George to wit providing Mr. Broder with a check which had insufficient funds. Mr. George has repaid the plaintiff the amount of the check that was insufficient and is currently negotiating to settle the claim for damages incurred.

The Company has recently received notice from a shareholder of the Company that such shareholder alleges that the Company has filed false and misleading documents with the SEC. Such shareholder claims that the Company had assets pursuant to its merger with Omni Assets, Inc. in 1999. To date no lawsuit has been commenced in this matter and the Company believes that these allegations have

no merit.

9. Subsequent Events

In June 2003, the Board approved and announced a 1-for-1000 reverse stock split. The Record date for said split was September 1, 2003 and a holder of a majority of the outstanding shares approved such split. As of the Record Date, our authorized capitalization consisted of 50,000,000 shares of common stock, par value \$0.00001 per share (the "Common Stock"), of which 27,600,000 were issued and outstanding. Pursuant to the reverse stock split, 1,000 shares of our Common Stock were converted into one share of Common Stock and there were 27,600 shares issued and outstanding after the split. The effective date of the reverse stock split was October 2, 2003.

The following table presents pro-forma weighted average outstanding shares and loss per share as if the reverse split were effectuated before September 30, 2003

	Inception Jan 17, 1983 to <u>Sept. 30, 2003</u>	Three Months Ended Sept. 30, 2003	Sept. 30, 2002	Nine Months Ended Sept. 30, 2003	Sept. 30, 2002
Net Loss	\$ (53,086)	\$ (8,031)	\$ (39)	\$ (17,463)	\$ (539)
Weighted Average Number of Shares Outstanding	<u>14,932</u>	<u>27,600</u>	<u>27,600</u>	<u>27,600</u>	<u>27,600</u>
Loss Per Share	\$ (3.56)	\$ (0.29)	\$ (0.00)	\$ (0.63)	\$ (0.02)

On October 29, 2003, pursuant to an Agreement and Plan of Acquisition the company acquired all of the outstanding shares of Medicos Laboratories, Inc., a Delaware corporation for the issuance of 1,975,000 shares to Varges George, the sole shareholder of Medicos Laboratories, Inc. In addition to the merger of Medicos Laboratories, Inc., on October 29, 2003, pursuant to an Agreement and Plan of Acquisition the company acquired all of the outstanding shares of Advanced Diagnostics, Inc. a Delaware corporation for the issuance of 3,000,000 shares to Varges George, the sole shareholder of Advanced Diagnostics, Inc. Mr. George is also the principal shareholder and President of Inamco International, Inc. Pursuant to these Agreements, Medicos Laboratories, Inc. and Advanced Diagnostics, Inc. became our wholly owned subsidiaries.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This discussion and analysis should be read in conjunction with our financial statements and accompanying notes included in this report and the financial statements and notes thereto for the interim period ended December 31, 2002 included in the Company's Form 10, as amended, as well as Form 10-KSB filed with the Securities and Exchange Commission on April 15, 2003.

Operating results are not necessarily indicative of results that may occur in future periods.

This discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Inamco assumes no obligation to update any forward-looking statement contained in this Form 10. The Company has had no change in its financial condition as a result of any operations, nor is there any liquidity, capital resources, results of operation, financial statements for any interim periods, material changes in financial position, or material changes from the result of operations.

Certain statements contained in this report on Form 10-QSB and other public statements that are not historical facts, including those statements that refer to our plans, goals, objectives, expectations, strategies, intentions and beliefs, constitute "forward-looking statements" within the meaning of the Private Securities

Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as "will," "may," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or similar words. You should not place undue reliance on these forward-looking statements. These statements involve risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied in our forward-looking statements. We assume no obligation to update these forward-looking statements as circumstances change in the future.

Inamco as of September 30, 2003, was a company that was in search of a merger/acquisition candidate in the generic pharmaceutical sector. The Company, being in its developmental stage, had no resources. Consequently, the Company needed, and still needs infusions of working capital either in the form of equity investments, loans or otherwise, in order to operate as a pharmaceutical concern.

As of September 30, 2003, the Company had yet to commence any operations and was seeking a proper merger and acquisition candidate to operate within the pharmaceutical drug sector.

Generic pharmaceuticals, as a whole, have the same chemical and therapeutic properties as their brand-named counterparts. Although typically less expensive, they are required to meet the same governmental standards as the brand-name drug, and most must receive approval from the appropriate regulatory authority prior to manufacture and sale.

As of September 30, 2003, Inamco had not spent any monies on company-sponsored research and development activities, and at that time, there were no plans to do so in the foreseeable future.

RESULTS OF OPERATIONS

NINE MONTHS ENDED SEPTEMBER 30, 2003 AND 2002

Revenues

None. For the nine and three months ended September 30, 2003 and 2002, the Company has had no revenue.

Research and Development

None. For the nine and three months ended September 30, 2003 and 2002, the Company has performed no research and development.

General and Administrative

General and administrative expenses are minimal, and for the nine and three months ended September 30, 2003 were \$17,463 and \$8,031 respectively compared to \$539 and \$39 for the same periods in September 2002. General and administrative expenses consist primarily of supporting administration of a public company and some professional fees. We expect that our general and administrative expenses will increase substantially once a merger and/or acquisition is consummated, in order to support our growth and requirements as a public company.

Non-Cash Stock-Based Compensation Charges

None. For the nine months ended September 30, 2003, the Company has not had any non-cash stock based deferred compensation.

Other Income, net

None. For the nine months ended September 30, 2003 and the year ended December 31, 2002, the Company has had no other income.

LIQUIDITY AND CAPITAL RESOURCES

As of September 30, 2003, we have accumulated a deficit of \$53,087. Our accumulated deficit is the result of expenses incurred in connection with the acquisition of the Company and general and administrative expenses. To date, we have funded our operations solely through loans from the majority shareholder and president of the Company, Mr. Varges George.

As of September 30, 2003, we had \$92 in cash and cash equivalents compared to \$927 in cash and cash equivalents as of December 31, 2002.

Net cash used for operations during the nine months ended September 30, 2003 was \$12,889 compared to \$2,192 for the same period in 2002. Net cash provided by Officers/Shareholders was approximately \$12,054 during the nine months ended September 30, 2003 compared to \$2,168 for the same period last year.

As of September 30, 2003, our Company had no business and/or operating history, and the success of the Company depended and currently depends, in part, upon the successful performance of the president and chief operating officer, Mr. Varges George. At present, the Company can make no assurances that it will ever have be profitable or achieve positive cash flow from operations.

The funding requirements of the Company may change at any time, and future capital requirements will depend on numerous factors, including scientific progress, additional personnel costs, progress in drug testing, the time and cost related to proposed regulatory approvals, if any, and the costs of filing certain applications. We cannot assure you that adequate funding will be available to us or, if available, that such funding will be available on acceptable terms. Any shortfall in funding could cause detrimental results to our Company's present business and future growth plans.

Item 3. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures.

Within the 90 days prior to the date of this report, Inamco International Corp. carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's Chief Executive and Principal Accounting Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures pursuant to Exchange Act Rule 13a-14. Based upon that evaluation, the Chief Executive and Principal Accounting Officer concluded that the Company's disclosure controls and procedures are effective in timely alerting him to material information required to be included in the Company's periodic SEC filings relating to the Company.

(b) Changes in Internal Controls.

There were no significant changes in the Company's internal controls or in other factors that could significantly affect these internal controls subsequent to the date of my most recent evaluation.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

On October 29, 2003, the Company, its subsidiaries and Varges George, the principal shareholder of the Company were sued by H. Neil Broder based on an alleged breach of contract claim. Mr. Broder alleges that he provided legal services to Mr. George to wit providing Mr. Broder with a check which had insufficient funds. Mr. George has repaid the plaintiff the amount of the check that was insufficient and is currently negotiating to settle the claim for damages incurred.

Advanced Diagnostics, Inc., a wholly owned subsidiary of the company effective October 29, 2003(see Note 9), recently received a letter from the Borough of South Plainfield stating that the it owes real estate taxes of approximately \$100,000. To date no action has been taken in this matter and the Company is prepared to pay such amount in full and is negotiating with the Township to determine the final amount owed.

The Company has recently received notice from a shareholder of the Company that such shareholder alleges that the Company has filed false and misleading documents with the SEC. Such shareholder claims that the Company had assets pursuant to its merger with Omni Assets, Inc. in 1999. To date

no lawsuit has been commenced in this matter and the Company believes that these allegations have no merit.

Item 2. Changes in Securities.

None

Item 3. Defaults Upon Senior Securities.

Not Applicable

Item 4. Submission of Matters to a Vote of Security Holders.

On September 1, 2003, a holder of the majority of the outstanding shares approved a 1-1,000 reverse split of the Company's outstanding shares.

Item 5. Other Information.

None

Item 6. Exhibits and Reports of Form 8-K.

On August 1, 2003, we filed an amendment to a Form 8K dated June 18, 2003 based on a change in our accountants.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INAMCO INTERNATIONAL, CORP.

Dated: November 19, 2003

By: /s/ VARGES GEORGE

Name: Varges George
Title: President, Chief Executive
Officer and Chief Financial Officer

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C 1350, AS ADOPTED, AND
THE REQUIREMENTS OF SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Varges George, Chief Executive Officer and Chief Financial Officer of Inamco International, Corp. (the "Company") do hereby certify that:

1. I have reviewed this quarterly report on Form 10-QSB of the Company;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; and
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the period presented in this quarterly report.
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Company and have:
 - (a) designed such disclosure controls and procedures to ensure that material information relating to the Company, is made known to me by others within the Company, particularly during the period in which this quarterly report is being prepared;
 - (b) evaluated the effectiveness of the Company's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and
 - (c) presented in this quarterly report my conclusions about the effectiveness of the disclosure controls and procedures based on my evaluation as of the Evaluation Date;
5. I have disclosed, based on my most recent evaluation, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions):
 - (a) all significant deficiencies in the design or operation of internal controls which could adversely affect the Company's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
 - (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal controls; and
6. I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of my most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

/s/ Varges George
Varges George
Chief Executive Officer and
Principal Accounting Officer

November 19, 2003

Exhibit 31

**CERTIFICATION OF
PRINCIPAL EXECUTIVE OFFICER
AND
CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350**

In connection with the accompanying Quarterly Report on Form 10-QSB (the "Report") of Inamco International Corp. (the "Company") for the quarter ended September 30, 2003, I, Varges George, Chief Executive Officer and Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief, that:

1. Such Quarterly Report on Form 10-QSB for the period ended September 30, 2003, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in such Quarterly Report on Form 10-QSB for the period ended September 30, 2003, fairly presents, in all material respects, the financial condition and results of operations of Inamco International Corp.

/s/ Varges George

Varges George

Chief Executive Officer and Chief Financial Officer

November 19, 2003